




IAP15 Rec'd PCT/PTO 09 NOV 2006

#6

Docket No.: 271529US0PCT



COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

RE: Application Serial No.: 10/533,081

Applicants: Hisamaru HIRAI, et al.

Filing Date: April 28, 2005

For: QUINOLINE DERIVATIVES AND QUINAZOLINE  
DERIVATIVES INHIBITING  
AUTOPHOSPHORYLATION OF FLT3 AND  
MEDICINAL COMPOSITIONS CONTAINING THE  
SAME

SIR:

Attached hereto for filing are the following papers:

**Renewed Request Under 37 CFR 1.42**

**Substitute Declaration and Power of Attorney for Patent Application (5 pp. executed)**

**Request for Extension of Time (five months)**

Our credit card payment form in the amount of **2,160.00** is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

Norman F. Oblon


Corwin P. Umbach, Ph.D.

Registration No. 40,211

Customer Number

**22850**

(703) 413-3000 (phone)  
(703) 413-2220 (fax)



DOCKET NO. 271529US0PCT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF

HISAMARU HIRAI, ET AL.

: EXAMINER:

SERIAL NO: 10/533,081

:

FILED: APRIL 28, 2005

: GROUP ART UNIT:

FOR: QUINOLINE DERIVATIVES AND  
QUINAZOLINE DERIVATIVES  
INHIBITING AUTOPHOSPHORYLATION  
OF FLT3 AND MEDICINAL  
COMPOSITIONS CONTAINING THE  
SAME

RECEIVED

5 FEB 2007

Legal Staff  
International Division

RENEWED REQUEST UNDER 37 CFR 1.42

MAIL STOP PCT  
COMMISSIONER FOR PATENTS  
OFFICE OF PCT LEGAL ADMINISTRATION  
P.O. BOX 1450  
ALEXANDRIA, VIRGINIA 22313

SIR:

In response to the Decision on Papers Filed Under 37 CFR 1.42 dated April 11, 2006, attached is a Declaration to satisfy the requirements of 35 U.S.C. 371(c)(4). Applicants respectfully request status under 37 CFR 1.42.

Respectfully submitted,

Customer Number  
**22850**

Tel: (703) 413-3000  
Fax: (703) 413 -2220  
(OSMMN 03/06)

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.  
Norman F. Oblon

*Corwin Paul Umbach*

Corwin P. Umbach, Ph.D.  
Registration No. 40,211



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Hisamaru HIRAI, et al.

SERIAL NO: 10/533,081

FILED: April 28, 2005

FOR: QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF FLT3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME

REQUEST FOR EXTENSION OF TIME  
UNDER 37 C.F.R. 1.136

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

It is hereby requested that a five month extension of time be granted to November 11, 2006 for

- filing a response to the Decision on Papers Filed Under 37 CFR §1.42 dated: April 11, 2006
- responding to the requirements in the Notice of Allowability dated:
- filing the Formal Drawings. The Issue Fee due        has been timely filed.
- responding to the Notice to File Missing Parts of Application dated:
- filing a Notice of Appeal. A timely response to the final rejection, due        has been filed.
- filing an Appeal Brief. A Notice of Appeal was filed on:
- Applicant claims small entity status. See 37 CFR 1.27. Therefore, the fee amount shown below is reduced by one-half.

The required fee of \$2,160.00 is enclosed herewith by credit card payment and any further charges may be made against the Attorney of Record's Deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.

11/15/2006 GFREY1 00000103 10533081  
01 FC:1255 2160.00 0P

Respectfully Submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.  
Norman F. Oblon

  
\_\_\_\_\_  
Corwin P. Umbach, Ph.D.  
Registration No. 40,211

Customer Number

22850

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)



## Substitute

# Declaration and Power of Attorney For Patent Application

## 特許出願宣言書及び委任状

### Japanese Language Declaration

### 日本語宣言書

下記の氏名の発明者として、私は以下の通り宣言します。

私の住所、郵便の宛先、国籍は下記の私の氏名の後に記載された通りです。

下記の名称の発明に関して請求範囲に記載され、特許出願している発明内容について、私が最初かつ唯一の発明者（下記の氏名が一つの場合）もしくは最初かつ共同発明者（下記の名称が複数の場合）であると信じています。

上記発明の明細書は、

本書に添付されています。  
 \_\_\_\_ 月 \_\_\_\_ 日に提出され、米国出願番号または特

許協定条約国際出願番号を

\_\_\_\_\_ とし、

（該当する場合） \_\_\_\_\_ に訂正されました。

私は、特許請求範囲を含む上記訂正後の明細書を検討し、内容を理解していることをここに表明します。

私は、連邦規則法典第 37 編第 1 条 56 項に定義されるとまり、特許資格の有無について重要な情報を開示する義務があることを認めます。

As a below named inventor, I hereby declare that:

My residence, mailing address and citizenship are as stated next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled.

QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF FLT3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME

the specification of which

is attached hereto.  
 was filed on April 28, 2005

as United States Application Number or PCT International Application Number

10/533,081 and was amended on  
January 12, 2006 (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56.

## Japanese Language Declaration (日本語宣言書)

私は、米国法典第 35 編 119 条(a) – (d)項又は 365 条 (b)項に基づき下記の、米国以外の国の少なくとも一ヵ国を指定している特許協力条約 365(a)項に基づく国際出願、又は外国での特許出願もしくは発明者証の出願についての外国優先権をここに主張するとともに、優先権を主張している、本出願の前に出願された特許または発明者証の外国出願を以下に、枠内をマークすることで、示しています。

### Prior Foreign Application(s) 外国での先行出願

2002-314670 (Number) (番号)	Japan (Country) (国名)
 (Number) (番号)	 (Country) (国名)

私は、第 35 編米国法典 119 条 (e) 項に基づいて下記の米国特許出願規定に記載された権利をここに主張いたします。

(Application No.) (出願番号)	(Filing Date) (出願日)
-----------------------------	------------------------

私は、下記の米国法典第 35 編 120 条に基づいて下記の米国特許出願に記載された権利、又は米国を指定している特許協力条約 365 条 (c) に基づく権利をここに主張します。また、本出願の各請求範囲の内容が米国法典第 35 編 112 条第 1 項又は特許協力条約で規定された方法で先行する米国特許出願に開示されていない限り、その先行米国出願書提出日以降で本出願書の日本国内または特許協力条約国際提出日までの期間中に入手された、連邦規則法典第 37 編 1 条 51 項で定義された特許資格の有無に関する重要な情報について開示義務があることを認識しています。

PCT/JP03/13848 (Application No.) (出願番号)	October 29, 2003 (Filing Date) (出願日)
 (Application No.) (出願番号)	 (Filing Date) (出願日)

I hereby claim foreign priority under Title 35, United States Code, § 119 (a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

### Priority Claimed 優先権主張

29/October/2002 (Day/Month/Year Filed) (出願年月日)	<input checked="" type="checkbox"/> Yes はい	<input type="checkbox"/> No いいえ
 (Day/Month/Year Filed) (出願年月日)	<input type="checkbox"/> Yes はい	<input type="checkbox"/> No いいえ

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

(Application No.) (出願番号)	(Filing Date) (出願日)
-----------------------------	------------------------

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s), or §365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

(Status: Patented, Pending, Abandoned)  
(現況 : 特許許可済、係属中、放棄済)

(Status: Patented, Pending, Abandoned)  
(現況 : 特許許可済、係属中、放棄済)

## Japanese Language Declaration (日本語宣言書)

私は、私自身の知識に基づいて本宣言書中で私が行なう表明が真実であり、かつ私の入手した情報と私の信じるところに基づく表明が全て真実であると信じていること、さらに故意になされた虚偽の表明及びそれと同等の行為は米国法典第18編第1001条に基づき、罰金または拘禁、もしくはその両方により処罰されること、そしてそのような故意による虚偽の声明を行なえば、出願した、又は既に許可された特許の有効性が失われることを認識し、よってここに上記のごとく宣誓を致します。

委任状：私は下記の発明者として、本出願に関する一切の手続きを米特許商標局に対して遂行する弁理士または代理人として、下記の者を指名いたします。

(弁護士、または代理人の指名及び登録番号を明記のこと)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: (list name and registration number)

Customer Number

22850

書類送付先

Send Correspondence to:

Customer Number

22850

直接電話連絡先：(名前及び電話番号)

Direct Telephone calls to: (name and telephone number)

(703) 413-3000

単独発明者または第1の共同発明者の氏名	Full name of sole or first joint inventor Atsushi MIWA	
発明者の署名	日付	First joint inventor's signature      Date <i>Atsushi Miwa</i> Oct. 17, 2006
住所	Residence c/o PHARMACEUTICAL RESEARCH LABORATORIES KIRIN BEER KABUSHIKI KAISHA 3, Miyahara-cho, Takasaki-shi Gunma 370-1295, Japan	
国籍	Citizenship Japan	
郵便の宛先	Mailing Address c/o PHARMACEUTICAL RESEARCH LABORATORIES KIRIN BEER KABUSHIKI KAISHA 3, Miyahara-cho, Takasaki-shi Gunma 370-1295, Japan	

**Japanese Language Declaration**  
**(日本語宣言書)**

第 2の共同発明者の氏名	Full name of second joint inventor, If any Tetsuya YOSHINO	
第 2の共同発明者の署名	日付	Second joint inventor's signature      Date <i>Tetsuya Yoshino Oct. 17, 2006</i>
住所	Residence c/o PHARMACEUTICAL RESEARCH LABORATORIES KIRIN BEER KABUSHIKI KAISHA 3, Miyahara-cho, Takasaki-shi Gunma 370-1295, Japan	
国籍	Citizenship Japan	
郵便の宛先	Mailing Address c/o PHARMACEUTICAL RESEARCH LABORATORIES KIRIN BEER KABUSHIKI KAISHA 3, Miyahara-cho, Takasaki-shi Gunma 370-1295, Japan	
第 3の共同発明者の氏名	Full name of third joint inventor, If any Mineo KUROKAWA	
第 3の共同発明者の署名	日付	Third joint inventor's signature      Date <i>MINEO KUROKAWA Oct. 25, 2006</i>
住所	Residence c/o UNIVERSITY OF TOKYO HOSPITAL 3-1, Hongo 7-chome, Bunkyo-ku Tokyo 113-8655, Japan	
国籍	Citizenship Japan	
郵便の宛先	Mailing Address c/o UNIVERSITY OF TOKYO HOSPITAL 3-1, Hongo 7-chome, Bunkyo-ku Tokyo 113-8655, Japan	

**Japanese Language Declaration**  
**(日本語宣言書)**

第 4 の共同発明者の氏名	Full name of fourth joint inventor, If any Hisamaru HIRAI (deceased)		
第 4 の共同発明者の署名	日付	Fourth joint inventor's signature	Date
住所	Residence		
国籍	Citizenship Japan		
郵便の宛先	Mailing Address		
第 4 の共同発明者の法定代理人	<p>Legal representative of fourth joint inventor</p> <p>I, Naoko HIRAI, (wife and heiress) am the legal representative of Hisamaru HIRAI, who is now deceased.</p> <p>I attest, upon information and belief, that the aforementioned facts are true.</p>		
第 4 の共同発明者の法定代理人の署名	Signature of legal representative of fourth joint inventor		
日付	<u>Naoko Hirai</u> Date <u>Oct. 26, 2006</u>		
第 4 の共同発明者の法定代理人の住所	Residence of legal representative of fourth joint inventor 4-23-13, Minamimagome, Ota-ku Tokyo 143-0025, JAPAN		
第 4 の共同発明者の法定代理人の国籍	Citizenship of legal representative of fourth joint inventor JAPAN		
第 4 の共同発明者の法定代理人の郵便の宛先	Mailing address of legal representative of fourth joint inventor 4-23-13, Minamimagome, Ota-ku Tokyo 143-0025, JAPAN		